Table 1 Demographics/characteristics of the populations analyzed
|  | Erenumab cohort (N = 3171) | OnabotA subgroup (N = 720) |
|---|---|---|
Age at index date, mean (SD) | 50.7 (13.6) | 51.1 (13.2) |
Female, n (%) | 2689 (84.8) | 628 (87.2) |
CM in 12 month pre-index period, n (%) | 1982 (62.5) | 685 (95.1) |
Index physician specialty, n (%) | ||
 Neurologist/headache specialist | 2159 (68.1) | 513 (71.3) |
 General practitioner | 439 (13.8) | 78 (10.8) |
 Nurse/physician assistant | 293 (9.2) | 68 (9.4) |
 Unknown/missing | 154 (4.9) | 34 (4.7) |
 Other specialist | 59 (1.9) | 11 (1.5) |
 Other HCP | 52 (1.6) | 12 (1.7) |
 Psychiatrist/psychologist | 15 (0.5) | 4 (0.6) |
Region, n (%) | ||
 South | 1536 (48.4) | 301 (41.8) |
 West | 684 (21.6) | 205 (28.5) |
 Midwest | 667 (21.0) | 146 (20.3) |
 Northeast | 284 (9.0) | 68 (9.4) |
Insurance type, n (%) | ||
 Point of service (POS) | 1569 (49.5) | 359 (49.9) |
 Other | 741 (23.4) | 179 (24.9) |
 Health maintenance organization (HMO) | 518 (16.3) | 114 (15.8) |
 Exclusive provider organization (EPO) | 214 (6.7) | 38 (5.3) |
 Preferred provider organization (PPO) | 129 (4.1) | 30 (4.2) |
Selected comorbidities in 12 month pre-index period (> 10%), n (%) | ||
 Anxiety | 1304 (41.1) | 343 (47.6) |
 CV disease | 1298 (40.9) | 304 (42.2) |
 Depression | 1295 (40.8) | 337 (46.8) |
 Insomnia | 731 (23.1) | 176 (24.4) |
 Obesity | 601 (19.0) | 141 (19.6) |
 Fibromyalgia | 434 (13.7) | 109 (15.1) |
 Constipation | 421 (13.3) | 113 (15.7) |